CNS Pharmaceuticals, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CNS Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-06-30 was $8.92K, a 98.77% decline year-over-year.
- CNS Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-03-31 was $12.40K, a 1936.95% increase year-over-year.
- CNS Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2023-06-30 was $725.06K.
- CNS Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2023-03-31 was $609.00.
- CNS Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2025 was $3.63K, a 82.99% decline from fiscal 2024.
- CNS Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2024 was $21.32K, a 99.28% decline from fiscal 2023.
- CNS Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2023 was $2.96M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2025-12-31 | $3.63K 10-K · filed 2026-03-31 | |
| 2024-12-31 | $21.32K 10-K · filed 2026-03-31 | |
| 2024-06-30 | $8.92K 10-Q · filed 2025-11-14 | |
| 2024-03-31 | $12.40K 10-Q · filed 2025-11-14 | |
| 2023-12-31 | $2.96M 10-K · filed 2025-03-31 | |
| 2023-06-30 | $725.06K 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $609.00 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |